Lanova Medicines Limited

This study tests a new combination of drugs (LM-108 and toripalimab) against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first treatment. About 400 adults will take part to see if the new combo helps them …

This early-phase study tests a new drug called LM-2417, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. A…

This early-phase study tests a new drug called LM-168, alone or with another drug (toripalimab), in 87 adults with advanced solid tumours that have stopped responding to standard treatments. The goal is to check safety and find the best dose, and to see if the drugs can shrink tu…

This early-stage study tests a new drug called LM-24C5 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 49 adults will take part in this open-labe…

This study tests an experimental drug called LM-350 in about 80 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The trial has two parts: first to check safety and dosing, then…

This study tests a new drug called LM-24C5 combined with other cancer treatments for people with advanced solid tumors that have a specific protein (CEACAM5). The goal is to see if the combination shrinks tumors and is safe. About 130 adults aged 18-80 whose cancer has returned o…